Cargando…

Feto-maternal outcomes and Glycemic control in Metformin versus insulin treated Gestational Diabetics

OBJECTIVE: To evaluate and compare feto-maternal outcomes and glycemic control in metformin versus insulin treated gestational diabetics. METHODS: The study was conducted in 2010- 2012 as a part of M. Phil at Civil hospital, Lyari General Hospital and Mamji Hospital in Karachi. After written informe...

Descripción completa

Detalles Bibliográficos
Autores principales: Arshad, Rabia, Khanam, Samia, Shaikh, Fuad, Karim, Nasim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Professional Medical Publications 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5673730/
https://www.ncbi.nlm.nih.gov/pubmed/29142561
http://dx.doi.org/10.12669/pjms.335.13286
_version_ 1783276630740828160
author Arshad, Rabia
Khanam, Samia
Shaikh, Fuad
Karim, Nasim
author_facet Arshad, Rabia
Khanam, Samia
Shaikh, Fuad
Karim, Nasim
author_sort Arshad, Rabia
collection PubMed
description OBJECTIVE: To evaluate and compare feto-maternal outcomes and glycemic control in metformin versus insulin treated gestational diabetics. METHODS: The study was conducted in 2010- 2012 as a part of M. Phil at Civil hospital, Lyari General Hospital and Mamji Hospital in Karachi. After written informed consent, 71 GDM diagnosed females with WHO criteria were enrolled. They were divided into two groups. Group-A, 32 females were given oral metformin 500 mg TDS while Group-B, 39 females were given insulin 0.8-0.9 mg/kg/day in two divided doses subcutaneously. Patients were followed till term. Feto-maternal outcomes were evaluated in 25 patients in each group who completed the study. RESULTS: When groups were compared, newborns in Group-B were significantly more in weight (p=0.01). Significant numbers of babies were delivered after 38 weeks of pregnancy in Group-B (P=0.021). There were two intrauterine deaths and significantly higher HbA(1)C at term in Group-B. (P=0.03). FBS at term was non-significant (p=0.079) and there was more number of cesarean sections due to feto-maternal disproportion in Group-B (28% vs.2%). Results analyzed for glycemic control before and after the treatment revealed that FBS was statistically less in Group-A (p=0.00) whereas for Group-B the value of FBS and HbA(1)C was statistically high. (p=0.002 & 0.04 respectively). CONCLUSION: Metformin has produced better effects on feto-maternal outcomes and glycemic control in comparison to Insulin in GDM.
format Online
Article
Text
id pubmed-5673730
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Professional Medical Publications
record_format MEDLINE/PubMed
spelling pubmed-56737302017-11-15 Feto-maternal outcomes and Glycemic control in Metformin versus insulin treated Gestational Diabetics Arshad, Rabia Khanam, Samia Shaikh, Fuad Karim, Nasim Pak J Med Sci Original Article OBJECTIVE: To evaluate and compare feto-maternal outcomes and glycemic control in metformin versus insulin treated gestational diabetics. METHODS: The study was conducted in 2010- 2012 as a part of M. Phil at Civil hospital, Lyari General Hospital and Mamji Hospital in Karachi. After written informed consent, 71 GDM diagnosed females with WHO criteria were enrolled. They were divided into two groups. Group-A, 32 females were given oral metformin 500 mg TDS while Group-B, 39 females were given insulin 0.8-0.9 mg/kg/day in two divided doses subcutaneously. Patients were followed till term. Feto-maternal outcomes were evaluated in 25 patients in each group who completed the study. RESULTS: When groups were compared, newborns in Group-B were significantly more in weight (p=0.01). Significant numbers of babies were delivered after 38 weeks of pregnancy in Group-B (P=0.021). There were two intrauterine deaths and significantly higher HbA(1)C at term in Group-B. (P=0.03). FBS at term was non-significant (p=0.079) and there was more number of cesarean sections due to feto-maternal disproportion in Group-B (28% vs.2%). Results analyzed for glycemic control before and after the treatment revealed that FBS was statistically less in Group-A (p=0.00) whereas for Group-B the value of FBS and HbA(1)C was statistically high. (p=0.002 & 0.04 respectively). CONCLUSION: Metformin has produced better effects on feto-maternal outcomes and glycemic control in comparison to Insulin in GDM. Professional Medical Publications 2017 /pmc/articles/PMC5673730/ /pubmed/29142561 http://dx.doi.org/10.12669/pjms.335.13286 Text en Copyright: © Pakistan Journal of Medical Sciences http://creativecommons.org/licenses/by/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Arshad, Rabia
Khanam, Samia
Shaikh, Fuad
Karim, Nasim
Feto-maternal outcomes and Glycemic control in Metformin versus insulin treated Gestational Diabetics
title Feto-maternal outcomes and Glycemic control in Metformin versus insulin treated Gestational Diabetics
title_full Feto-maternal outcomes and Glycemic control in Metformin versus insulin treated Gestational Diabetics
title_fullStr Feto-maternal outcomes and Glycemic control in Metformin versus insulin treated Gestational Diabetics
title_full_unstemmed Feto-maternal outcomes and Glycemic control in Metformin versus insulin treated Gestational Diabetics
title_short Feto-maternal outcomes and Glycemic control in Metformin versus insulin treated Gestational Diabetics
title_sort feto-maternal outcomes and glycemic control in metformin versus insulin treated gestational diabetics
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5673730/
https://www.ncbi.nlm.nih.gov/pubmed/29142561
http://dx.doi.org/10.12669/pjms.335.13286
work_keys_str_mv AT arshadrabia fetomaternaloutcomesandglycemiccontrolinmetforminversusinsulintreatedgestationaldiabetics
AT khanamsamia fetomaternaloutcomesandglycemiccontrolinmetforminversusinsulintreatedgestationaldiabetics
AT shaikhfuad fetomaternaloutcomesandglycemiccontrolinmetforminversusinsulintreatedgestationaldiabetics
AT karimnasim fetomaternaloutcomesandglycemiccontrolinmetforminversusinsulintreatedgestationaldiabetics